A Phase 3 interventional study of Beclomethasone dipropionate BAI and Placebo BAI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 102 sites in 5 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-11-09.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.
Among the 40 studies testing beclomethasone in Asthma, this one is the 6th largest by enrollment, is one of 5 that started in 2013, is one of 20 in phase 3, and was the 26th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →
Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 22 · Phase 4 9
First in 1995; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 628 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 67 across the 40 interventional studies. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
54 studies in Asthma by Teva Pharmaceutical Industries, Ltd.: none open now, 1 under way, 1 of them phase 3. Of 52 finished, 36 (69%) have results posted.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 14th largest by enrollment of the 51 interventional ones that give a count, is one of 8 that started in 2013, is one of 30 in phase 3, and was the 27th registered.
Teva Pharmaceutical Industries, Ltd.’s Asthma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing beclomethasone in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Teva Pharmaceutical Industries, Ltd.’s 54 in Asthma:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 years of age with persistent asthma, compared with placebo.
Patients took 1 inhalation (with assistance from parents/guardians/caregivers, as needed) from each of 2 devices (BAI device followed by MDI device in that order) twice daily as per the double-dummy study design: 1 BAI treatment or placebo device and 1 MDI treatment or placebo device for a total of 2 inhalations each time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day). Placebo MDI twice daily for blinding. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.
Drug: Beclomethasone dipropionate BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Placebo MDI
Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day). Placebo MDI twice daily for blinding. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.
Drug: Beclomethasone dipropionate BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Placebo MDI
Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day). Placebo BAI twice daily for blinding. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.
Drug: Placebo BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Beclomethasone dipropionate MDI
Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day). Placebo BAI twice daily for blinding. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.
Drug: Placebo BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Beclomethasone dipropionate MDI
Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily. Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study.
Drug: Placebo BAI · Drug: albuterol/salbutamol 90 mcg · Drug: Placebo MDI
Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
Also known as: BDP, breath-actuated inhaler
Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
Also known as: breath-actuated inhaler
Drug page: Albuterol
Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
Also known as: bronchodilators
Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
Also known as: BDP, metered-dose inhaler, QVAR®
Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk))
Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. Baseline was defined as baseline trough morning percent predicted FEV1. Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest ('best attempt') FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 8 attempts) was used.
Time frame: Day 1 (baseline), Weeks 2, 4, 8, 12
Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period
The analysis of change from baseline in weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) PEF calculated across the 12-week treatment period was performed using a mixed model for repeated measures (MMRM) with effects due to baseline weekly average of daily trough morning PEF.
Time frame: Day 1 (baseline), weeks 1-12
Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period
The analysis of change from baseline in the weekly average of daily evening PEF across the 12-week treatment period was performed using a mixed model for repeated measures (MMRM) with effects due to baseline weekly average of daily evening PEF.
Time frame: Day 1 (baseline), weeks 1-12
Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12
The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) across the 12 weeks was analyzed using a mixed model for repeated measures (MMRM).
Time frame: Day 1 (baseline), weeks 1-12
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12
The total daily asthma symptom score is the average of the daytime and nighttime scores analyzed using an mixed model for repeated measures (MMRM). Baseline was defined as the average of recorded morning and evening asthma symptom scores over the 7 days before randomization. Daytime Scores range from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities; Nighttime Scores range from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The daily asthma symptom score was therefore 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night.
Time frame: Day 1 (baseline), weeks 1-12
Kaplan-Meier Estimates For Time to Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-week Treatment Period
Time to withdrawal due to meeting stopping criteria was defined as number of days elapsed from the date of first dose of double-blind study treatment to the date of withdrawal due to meeting stopping criteria. Kaplan-Meier estimates (median and 95% CI of the median) are not applicable if the proportion of participants withdrawn is less than 0.5.
Time frame: Day 1 to 12 weeks
Patients were screened at 123 centers in Croatia, Mexico, Poland, Ukraine, and the United States. The intent-to-treat (ITT) population included all randomly assigned patients
| Milestone | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI |
|---|---|---|---|---|---|
| Started | 127 | 126 | 125 | 125 | 125 |
| Completed | 109 | 116 | 113 | 112 | 112 |
| Not completed | 18 | 10 | 12 | 13 | 13 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 3 | 2 | 3 | 2 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 1 | 2 | 3 | 0 |
| Withdrew: Lost to follow-up | 4 | 1 | 3 | 1 | 4 |
| Withdrew: Not reported | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 6 | 3 | 4 | 6 | 5 |
Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. Baseline was defined as baseline trough morning percent predicted FEV1. Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest ('best attempt') FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 8 attempts) was used.
| liters | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI |
|---|---|---|---|---|---|
| Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk)) | 2.62 ± 0.744 | 5.43 ± 0.742 | 3.25 ± 0.732 | 3.54 ± 0.734 | 3.71 ± 0.734 |
The analysis of change from baseline in weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) PEF calculated across the 12-week treatment period was performed using a mixed model for repeated measures (MMRM) with effects due to baseline weekly average of daily trough morning PEF.
| liters | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI |
|---|---|---|---|---|---|
| Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period | 4.3 ± 2.11 | 15.6 ± 2.08 | 12.8 ± 2.12 | 11.9 ± 2.11 | 10.8 ± 2.11 |
The analysis of change from baseline in the weekly average of daily evening PEF across the 12-week treatment period was performed using a mixed model for repeated measures (MMRM) with effects due to baseline weekly average of daily evening PEF.
| liters | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI |
|---|---|---|---|---|---|
| Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period | 1.4 ± 2.11 | 13.1 ± 2.09 | 11.4 ± 2.12 | 11.3 ± 2.12 | 10.1 ± 2.12 |
The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) across the 12 weeks was analyzed using a mixed model for repeated measures (MMRM).
| Number of inhalations | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI |
|---|---|---|---|---|---|
| Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12 | -0.36 ± 0.069 | -0.72 ± 0.068 | -0.50 ± 0.069 | -0.41 ± 0.069 | -0.54 ± 0.069 |
The total daily asthma symptom score is the average of the daytime and nighttime scores analyzed using an mixed model for repeated measures (MMRM). Baseline was defined as the average of recorded morning and evening asthma symptom scores over the 7 days before randomization. Daytime Scores range from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities; Nighttime Scores range from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The daily asthma symptom score was therefore 0 - 9 with 0=no symptoms during the day or night and 9=severe symptoms both day and night.
| units on a scale | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI |
|---|---|---|---|---|---|
| Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12 | -0.27 ± 0.036 | -0.44 ± 0.036 | -0.36 ± 0.036 | -0.31 ± 0.036 | -0.36 ± 0.036 |
Time to withdrawal due to meeting stopping criteria was defined as number of days elapsed from the date of first dose of double-blind study treatment to the date of withdrawal due to meeting stopping criteria. Kaplan-Meier estimates (median and 95% CI of the median) are not applicable if the proportion of participants withdrawn is less than 0.5.
| Days | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI |
|---|---|---|---|---|---|
| Kaplan-Meier Estimates For Time to Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-week Treatment Period | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over - Run-In: Days -21 to Day 0 - Double-blind Study Treatment: Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Placebo | — | 0/628 (0%) | 1/628 (0.2%) |
| Placebo BAI and MDI | — | 0/127 (0%) | 8/127 (6.3%) |
| BDP 80 mcg BAI | — | 0/126 (0%) | 6/126 (4.8%) |
| BDP 160 mcg BAI | — | 0/125 (0%) | 13/125 (10.4%) |
| BDP 80 mcg MDI | — | 0/125 (0%) | 15/125 (12%) |
| BDP 160 mcg MDI | — | 0/125 (0%) | 11/125 (8.8%) |
| Event | Run-in Placebo | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/628 | 4/127 | 5/126 | 11/125 | 6/125 | 6/125 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/628 | 4/127 | 1/126 | 3/125 | 9/125 | 6/125 |
Intent to treat (ITT) population
| Age, Continuous(years) | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI | Total |
|---|---|---|---|---|---|---|
| Mean | 8.2 ± 2.06 | 8.5 ± 2.10 | 8.4 ± 1.24 | 8.2 ± 1.78 | 8.4 ± 1.86 | 8.3 ± 1.93 |
| Sex: Female, Male(Participants) | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI | Total |
|---|---|---|---|---|---|---|
| Female | 41 | 52 | 46 | 49 | 50 | 238 |
| Male | 86 | 74 | 79 | 76 | 75 | 390 |
| Race (NIH/OMB)(Participants) | Placebo BAI and MDI | BDP 80 mcg BAI | BDP 160 mcg BAI | BDP 80 mcg MDI | BDP 160 mcg MDI | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 4 | 4 | 3 | 1 | 15 |
| Asian | 0 | 2 | 2 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 42 | 34 | 33 | 37 | 49 | 195 |
| White | 71 | 69 | 69 | 76 | 63 | 348 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 11 | 17 | 17 | 9 | 12 | 66 |
Showing the first 100 of 102 sites across 5 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2013, a primary completion of Feb 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone
Teva Branded Pharmaceutical Products R&D, Inc. →